214 related articles for article (PubMed ID: 34146913)
1. Non-carbohydrate strategies to inhibit lectin proteins with special emphasis on galectins.
Sethi A; Sanam S; Alvala M
Eur J Med Chem; 2021 Oct; 222():113561. PubMed ID: 34146913
[TBL] [Abstract][Full Text] [Related]
2. An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016-present).
Sethi A; Sanam S; Alvala R; Alvala M
Expert Opin Ther Pat; 2021 Aug; 31(8):709-721. PubMed ID: 33749494
[TBL] [Abstract][Full Text] [Related]
3. Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.
Wdowiak K; Francuz T; Gallego-Colon E; Ruiz-Agamez N; Kubeczko M; Grochoła I; Wojnar J
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29320431
[TBL] [Abstract][Full Text] [Related]
4. Analysis of selected blood and immune cell responses to carbohydrate-dependent surface binding of proto- and chimera-type galectins.
Timoshenko AV; Gorudko IV; Maslakova OV; André S; Kuwabara I; Liu FT; Kaltner H; Gabius HJ
Mol Cell Biochem; 2003 Aug; 250(1-2):139-49. PubMed ID: 12962152
[TBL] [Abstract][Full Text] [Related]
5. Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin.
Vladoiu MC; Labrie M; Létourneau M; Egesborg P; Gagné D; Billard É; Grosset AA; Doucet N; Chatenet D; St-Pierre Y
Oncotarget; 2015 Dec; 6(38):40970-80. PubMed ID: 26543238
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of galectins with small molecules.
Oberg CT; Leffler H; Nilsson UJ
Chimia (Aarau); 2011; 65(1-2):18-23. PubMed ID: 21469439
[TBL] [Abstract][Full Text] [Related]
7. NMR Investigation of Protein-Carbohydrate Interactions: The Recognition of Glycans by Galectins Engineered with Fluorotryptophan Residues.
Lete MG; Franconetti A; Bertuzzi S; Delgado S; Azkargorta M; Elortza F; Millet O; Jiménez-Osés G; Arda A; Jiménez-Barbero J
Chemistry; 2023 Jan; 29(5):e202202208. PubMed ID: 36343278
[TBL] [Abstract][Full Text] [Related]
8. Galectin-8. A new rat lectin, related to galectin-4.
Hadari YR; Paz K; Dekel R; Mestrovic T; Accili D; Zick Y
J Biol Chem; 1995 Feb; 270(7):3447-53. PubMed ID: 7852431
[TBL] [Abstract][Full Text] [Related]
9. Galectin-Carbohydrate Interactions in Biomedicine and Biotechnology.
Laaf D; Bojarová P; Elling L; Křen V
Trends Biotechnol; 2019 Apr; 37(4):402-415. PubMed ID: 30413271
[TBL] [Abstract][Full Text] [Related]
10. Binding and cross-linking properties of galectins.
Fred Brewer C
Biochim Biophys Acta; 2002 Sep; 1572(2-3):255-62. PubMed ID: 12223273
[TBL] [Abstract][Full Text] [Related]
11. Significance of sugar chain recognition by galectins and its involvement in disease-associated glycosylation.
Arikawa T; Simamura E; Shimada H; Nakamura T; Hatta T; Shoji H
Congenit Anom (Kyoto); 2014 May; 54(2):77-81. PubMed ID: 24450300
[TBL] [Abstract][Full Text] [Related]
12. Determination of carbohydrate-binding preferences of human galectins with carbohydrate microarrays.
Horlacher T; Oberli MA; Werz DB; Kröck L; Bufali S; Mishra R; Sobek J; Simons K; Hirashima M; Niki T; Seeberger PH
Chembiochem; 2010 Jul; 11(11):1563-73. PubMed ID: 20572248
[TBL] [Abstract][Full Text] [Related]
13. Activity-structure correlations in divergent lectin evolution: fine specificity of chicken galectin CG-14 and computational analysis of flexible ligand docking for CG-14 and the closely related CG-16.
Wu AM; Singh T; Liu JH; Krzeminski M; Russwurm R; Siebert HC; Bonvin AM; André S; Gabius HJ
Glycobiology; 2007 Feb; 17(2):165-84. PubMed ID: 17060369
[TBL] [Abstract][Full Text] [Related]
14. The Galβ-(syn)-gauche configuration is required for galectin-recognition disaccharides.
Iwaki J; Tateno H; Nishi N; Minamisawa T; Nakamura-Tsuruta S; Itakura Y; Kominami J; Urashima T; Nakamura T; Hirabayashi J
Biochim Biophys Acta; 2011 Jul; 1810(7):643-51. PubMed ID: 21514365
[TBL] [Abstract][Full Text] [Related]
15. Calix[n]arene-based glycoclusters: bioactivity of thiourea-linked galactose/lactose moieties as inhibitors of binding of medically relevant lectins to a glycoprotein and cell-surface glycoconjugates and selectivity among human adhesion/growth-regulatory galectins.
André S; Sansone F; Kaltner H; Casnati A; Kopitz J; Gabius HJ; Ungaro R
Chembiochem; 2008 Jul; 9(10):1649-61. PubMed ID: 18509838
[TBL] [Abstract][Full Text] [Related]
16. Galectins-1 and -3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity.
André S; Kojima S; Yamazaki N; Fink C; Kaltner H; Kayser K; Gabius HJ
J Cancer Res Clin Oncol; 1999; 125(8-9):461-74. PubMed ID: 10480338
[TBL] [Abstract][Full Text] [Related]
17. Dissecting the Structure-Activity Relationship of Galectin-Ligand Interactions.
Chan YC; Lin HY; Tu Z; Kuo YH; Hsu SD; Lin CH
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382172
[TBL] [Abstract][Full Text] [Related]
18. Linear triazole-linked pseudo oligogalactosides as scaffolds for galectin inhibitor development.
Dussouy C; Kishor C; Lambert A; Lamoureux C; Blanchard H; Grandjean C
Chem Biol Drug Des; 2020 Oct; 96(4):1123-1133. PubMed ID: 32220037
[TBL] [Abstract][Full Text] [Related]
19. Enzymatic synthesis of non-natural trisaccharides and galactosides; Insights of their interaction with galectins as a function of their structure.
Porciúncula González C; Cagnoni AJ; Mariño KV; Fontana C; Saenz-Méndez P; Irazoqui G; Giacomini C
Carbohydr Res; 2019 Jan; 472():1-15. PubMed ID: 30428394
[TBL] [Abstract][Full Text] [Related]
20. Defining the potential of aglycone modifications for affinity/selectivity enhancement against medically relevant lectins: synthesis, activity screening, and HSQC-based NMR analysis.
Rauthu SR; Shiao TC; André S; Miller MC; Madej É; Mayo KH; Gabius HJ; Roy R
Chembiochem; 2015 Jan; 16(1):126-39. PubMed ID: 25407851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
